Loading…
Employees: 1,611
Size ASKA Pharmaceutical (4886.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $342M, the 1276th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥2,026 on 6 Nov 2026.
Performance Over six months the shares fell 30.5%, against -20.1% for the median peer and +1.8% for the Japan market (cap-weighted) — 5th lowest of 19 in its peer set.
Growth Revenue grew 10.9% over the last twelve months (peer median -5.7%).
Valuation It trades at 12.3× forward earnings against a peer median of 27.7× (2nd cheapest of 5).
Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | ¥71.1B | ¥64.1B | ¥62.8B | ¥60.5B |
| Revenue growth | — | +11% | +2% | +4% | — |
| Gross profit | n/a | ¥34.1B | ¥31.3B | ¥30.7B | ¥28.6B |
| EBITDA | n/a | ¥8.92B | ¥7.58B | ¥9.16B | ¥8.24B |
| Net income | ¥5.21B | ¥5.42B | ¥5.10B | ¥7.54B | ¥4.24B |
| Free cash flow | n/a | ¥3.75B | -¥475M | ¥166M | ¥2.89B |
| Capital expenditure | n/a | ¥2.87B | ¥3.56B | ¥1.45B | ¥746M |
| Total debt | ¥9.91B | ¥11.4B | ¥10.9B | ¥9.48B | ¥12.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4886.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -10.4% | 2nd highest of 19 |
| 6-month return | -30.5% | -20.1% | 5th lowest of 19 |
| Distance from 52-week high | -33.5% | -33.2% | 10th lowest of 20 |
| Revenue growth (TTM) | +10.9% | -5.7% | 5th highest of 19 |
| Forward P/E | 12.3× | 27.7× | 2nd cheapest of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ASKA Pharmaceutical 4886.T | Japan | $342M | -31% | +11% | n/a | 12.3× | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 295.1× | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | n/a | n/a | n/a |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | n/a | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |
| Opus Genetics IRD | United States | $348M | -19% | -36% | -513% | n/a | n/a | n/a |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | n/a | n/a | n/a |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | n/a | 28.5% | -6.4% |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 8.1× | -6.6% | +24.8% |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | n/a | 58.0% | -12.8% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | n/a | -10.4% | +10.3% |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | n/a | n/a | n/a |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | n/a | n/a | n/a |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | n/a | 22.5% | +0.5% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | n/a | 15.1% | +7.3% |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 35.3× | 10.5% | +4.2% |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 20.2× | 37.7% | -3.2% |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | n/a | 2.5% | -4.9% |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | n/a | n/a | n/a |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |